Cost-Minimisation Analysis of Saxagliptin Compared to Sitagliptin And Linagliptin As Triple Therapy In Combination With Metformin And A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.

H Vioix,L.A Eddowes,Z Gabriel,M Griffiths

doi:10.1016/j.jval.2014.08.720

Cost-Minimisation Analysis of Saxagliptin Compared to Sitagliptin And Linagliptin As Triple Therapy In Combination With Metformin And A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.

H Vioix, L.A Eddowes + Show 2 more

Open Access

https://doi.org/10.1016/j.jval.2014.08.720

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Oct 26, 2014
License type: publisher-specific-oa

Affiliation: AstraZeneca (United Kingdom), Costello Medical Consulting (United Kingdom)

#Uk Health Care Perspective #Triple Therapy In Combination + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Cost-Minimisation Analysis of Saxagliptin Compared to Sitagliptin And Linagliptin As Triple Therapy In Combination With Metformin And A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.

Full Text